| Home > Zentren > Zentrum für Operative Medizin > Klinik und Poliklinik für Urologie > Publikationen 2012
1.
Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy.
Rink M, Zabor EC, Furberg H, Xylinas E, Ehdaie B, Novara G, Babjuk M, Pycha A, Lotan Y, Trinh QD, Chun FK, Lee RK, Karakiewicz PI, Fisch M, Robinson BD, Scherr DS, Shariat SF.
Eur Urol. 2012 Nov 27. doi:pii: S0302-2838(12)01414-5. 10.1016/j.eururo.2012.11.039.
2.
Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.
Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz PI, Gontero P, Chun FK, Fisch M, Scherr DS, Shariat SF.
World J Urol. 2012 Nov 30.
3.
Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma.
Eichelberg C, Chun FK, Bedke J, Heuer R, Adam M, Moch H, Terracciano L, Hinrichs K, Dahlem R, Fisch M, Schlomm T, Sauter G, Minner S.
Int J Cancer. 2012 Nov 26. doi: 10.1002/ijc.27970.
4.
Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer.
Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, Lotan Y, Sun M, Karakiewicz PI, Abdennabi J, Fajkovic H, Loidl W, Chun FK, Fisch M, Scherr DS, Shariat SF.
J Urol. 2012 Dec;188(6):2120-8. doi: 10.1016/j.juro.2012.08.029
5.
Etiology and outcome of the perineal repair of posterior and bulbar urethral strictures in children: A single surgeon experience.
Pfalzgraf D, Isbarn H, Meyer-Moldenhauer WH, Fisch M, Riechardt S.
J Pediatr Urol. 2012 Oct 13. doi:pii: S1477-5131(12)00230-6. 10.1016/j.jpurol.2012.09.007.
6.
Urethral 'cripples': two-staged procedures.
Riechardt S, Dahlem R, Fisch M.
Curr Opin Urol. 2012 Nov;22(6):484-6. doi: 10.1097/MOU.0b013e328357bc8b.
7.
The Barbagli technique: 3-year experience with a modified approach.
Pfalzgraf D, Kluth L, Isbarn H, Reiss P, Riechardt S, Fisch M, Dahlem R.
BJU Int. 2012 Sep 18. doi: 10.1111/j.1464-410X.2012.11399.x. [Epub ahead of print]
8.
Editorial comment on urethral reconstruction.
Fisch M.
Curr Opin Urol. 2012 Nov;22(6):445-6. doi: 10.1097/MOU.0b013e328358fee4.
9.
Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay.
Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, Shariat SF, Chun FK.
Eur Urol. 2012 Jul 20.
10.
External validation of the updated briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection.
Hansen J, Rink M, Bianchi M, Kluth LA, Tian Z, Ahyai SA, Shariat SF, Briganti A, Steuber T, Fisch M, Graefen M, Karakiewicz PI, Chun FK.
Prostate. 2012 Jul 20. doi: 10.1002/pros.22559. [Epub ahead of print]
11.
Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy.
Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF.
BJU Int. 2012 Jul 13. doi: 10.1111/j.1464-410X.2012.11370.x. [Epub ahead of print]
12.
Dual source computed tomography coronary angiography in new onset cardiomyopathy.
Srichai MB, Fisch M, Hecht E, Slater J, Rachofsky E, Hays AG, Babb J, Jacobs JE.
World J Radiol. 2012 Jun 28;4(6):258-64. doi: 10.4329/wjr.v4.i6.258.
13.
[Urinary diversion and colon: transverse conduit and transverse pouch].
Ahyai SA, Sayedahmed K, Engel O, Chun F, Dahlem R, Fisch M.
Urologe A. 2012 Jul;51(7):937-46. doi: 10.1007/s00120-012-2907-5. German.
14.
Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer.
Minner S, De Silva C, Rink M, Dahlem R, Chun F, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W.
Pathology. 2012 Aug;44(5):448-52. doi: 10.1097/PAT.0b013e32835576ee.
15.
Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.
Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF; for the Upper Tract Urothelial Carcinoma Collaboration.
Eur Urol. 2012 Jun 22. [Epub ahead of print]
16.
[Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].
Rink M, Adam M, Hansen J, Chun FK, Ahyai SA, Remzi M, Schlomm T, Engel O, Heuer R, Eichelberg C, Fisch M, Dahlem R, Shariat SF.
Urologe A. 2012 Sep;51(9):1228-39. doi: 10.1007/s00120-012-2911-9. German.
17.
[Comments on pyeloplasty - laparoscopic versus robotic].
Fisch M.
Urologe A. 2012 May;51(5):645. doi: 10.1007/s00120-012-2883-9. German.
18.
Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
Budäus L, Isbarn H, Tennstedt P, Salomon G, Schlomm T, Steuber T, Haese A, Chun F, Fisch M, Michl U, Heinzer H, Huland H, Graefen M.
BJU Int. 2012 Dec;110(11):1714-20. doi: 10.1111/j.1464-410X.2012.11147.x. Epub 2012 Apr 23.
19.
[Secondary malignancies in urinary diversions].
Kälble T, Hofmann I, Thüroff JW, Stein R, Hautmann R, Riedmiller H, Vergho D, Hertle L, Wülfing C, Truß M, Roth S, von Rundstedt FC, Albers P, Gschwend J, Herkommer K, Humke U, Spahn M, Bader P, Steffens J, Harzmann R, Stief CG, Karl A, Müller SC, Waldner M, Noldus J, Kleinschmidt K, Alken P, Kopper B, Fisch M, Lampel A, Stenzel A, Fichtner J, Flath B, Rübben H, Juenemann KP, Hautmann S, Knipper A, Leusmann D, Strohmaier W, Thon WF, Miller S, Weingärtner K, Schilling A, Piechota H, Becht JE, Schwaibold H, Bub P, Conrad S, Wenderoth U, Merkle W, Rösch W, Otto T, Ulshöfer B, Westenfelder M.
Urologe A. 2012 Apr;51(4):500, 502-6. doi: 10.1007/s00120-012-2815-8. German.
20.
[Management of urinary incontinence after orthotopic urinary diversion].
Soave A, Dahlem R, Rink M, Ahyai S, Fisch M.
Urologe A. 2012 Apr;51(4):494-9. doi: 10.1007/s00120-012-2814-9. German.
21.
[Sigmoid-rectum pouch: a modification of the ureterosigmoidostomy].
Fisch M.
Aktuelle Urol. 2012 Mar;43(2):123-33. doi: 10.1055/s-0029-1233515. Epub 2012 Mar 27.
22.
Transurethral holmium laser enucleation versus transurethral resection of the prostate and simple open prostatectomy--which procedure is faster?
Ahyai SA, Chun FK, Lehrich K, Dahlem R, Zacharias MS, Fisch M, Kuntz RM.
J Urol. 2012 May;187(5):1608-13. doi: 10.1016/j.juro.2011.12.107. Epub 2012 Mar 14.
23.
Biomolecular predictors of urothelial cancer behavior and treatment outcomes.
Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, Sagalowsky AI, Chun FK, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF.
Curr Urol Rep. 2012 Apr;13(2):122-35. doi: 10.1007/s11934-012-0237-1. Review.
24.
Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.
Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; Bladder Cancer Research Consortium (BCRC); Upper Tract Urothelial Carcinoma Collaboration (UTUCC).
Eur Urol. 2012 Oct;62(4):677-84. Epub 2012 Feb 15.
25.
Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis.
Schmitges J, Trinh QD, Sun M, Hansen J, Bianchi M, Jeldres C, Perrotte P, Dahlem R, Shariat SF, Chun FK, Montorsi F, Menon M, Fisch M, Graefen M, Karakiewicz PI.
BJU Int. 2012 Sep;110(6 Pt B):E183-90. doi: 10.1111/j.1464-410X.2012.10936.x. Epub 2012 Feb 9.
26.
[Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies].
Rink M, Chun FK, Chromecki TF, Fajkovic H, Dahlem R, Fisch M, Shariat SF.
Urologe A. 2012 Jun;51(6):820-8. doi: 10.1007/s00120-011-2769-2. Review. German.
27.
Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, Friedrich MG, Shariat SF, Fisch M, Pantel K, Riethdorf S.
Eur Urol. 2012 Apr;61(4):810-7. doi: 10.1016/j.eururo.2012.01.017. Epub 2012 Jan 20.
28.
Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma.
Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, Moch H, Wilczak W, Bokemeyer C, Fisch M, Sauter G, Eichelberg C.
Cancer. 2012 Mar 1;118(5):1268-75. doi: 10.1002/cncr.26436.
29.
Two-stage urethroplasty with buccal mucosa.
Riechardt S, Fisch M.
BJU Int. 2012 Jan;109(1):150-62. doi: 10.1111/j.1464-410X.2011.10842.x. No abstract available.
30.
Satisfaction with genital surgery and sexual life of adults with XY disorders of sex development: results from the German clinical evaluation study.
Köhler B, Kleinemeier E, Lux A, Hiort O, Fisch M, Grüters A, Thyen U; DSD Network Working Group.
J Clin Endocrinol Metab. 2012 Feb;97(2):577-88. doi: 10.1210/jc.2011-1441. Epub 2011 Nov 16.
31.
A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.
BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.
32.
Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Non-muscle-invasive Bladder Cancer.
Rink M, Xylinas E, Babjuk M, Pycha A, Karakiewicz PI, Novara G, Dahlem R, Shariat SF.
Eur Urol. 2012 Dec;62(6):1204-6. doi: 10.1016/j.eururo.2012.08.057. Epub 2012 Sep 5. No abstract available.
33.
Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.
Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Engel O, Chun FK, Dahlem R, Rubin MA, Shariat SF, Mosquera JM.
Urol Oncol. 2012 Sep 1. doi:pii: S1078-1439(12)00237-2. 10.1016/j.urolonc.2012.06.011. [Epub ahead of print]
34.
Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy.
Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, Shariat SF.
35.
Protocol-based active surveillance for low-risk prostate cancer: anxiety levels in both men and their partners.
Seiler D, Randazzo M, Leupold U, Zeh N, Isbarn H, Chun FK, Ahyai SA, Baumgartner M, Huber A, Recker F, Kwiatkowski M.
Urology. 2012 Sep;80(3):564-9. doi: 10.1016/j.urology.2012.04.053. Epub 2012 Jul 7.
36.
The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy.
Schmitges J, Trinh QD, Bianchi M, Sun M, Abdollah F, Ahyai SA, Jeldres C, Steuber T, Perrotte P, Shariat SF, Menon M, Montorsi F, Graefen M, Karakiewicz PI.
Int Urol Nephrol. 2012 Jun;44(3):799-806. doi: 10.1007/s11255-011-0103-y. Epub 2011 Dec 13.
37.
Benign prostatic hyperplasia and lower urinary tract symptoms: research priorities.
De Nunzio C, Ahyai S, Autorino R, Bachmann A, Bialek W, Briganti A, Reich O, Sosnowski R, Thiruchelvam N, Novara G; European Association of Urology Young Academic Urologists BPH Group.
Eur Urol. 2011 Dec;60(6):1205-6. doi: 10.1016/j.eururo.2011.08.055. Epub 2011 Sep 7.
38.
Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy.
Bedke J, Chun FK, Merseburger A, Scharpf M, Kasprzyk K, Schilling D, Sievert KD, Stenzl A, Kruck S.
BJU Int . 2012 Nov 7. doi: 10.1111/j.1464-410X.2012.11642.x.
39.
Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis.
Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R; on behalf of the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).
Eur Urol. 2012 Sep 5.
40.
Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.
Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF; for the Bladder Cancer Research Consortium.
BJU Int. 2012 Sep 3. doi: 10.1111/j.1464-410X.2012.11433.x. [Epub ahead of print]
41.
Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer.
Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, Scherr DS, Shariat SF.
Eur Urol. 2012 Aug 21. [Epub ahead of print]
42.
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?
Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS.
World J Urol. 2012 Dec;30(6):807-14. doi: 10.1007/s00345-012-0910-5. Epub 2012 Jul 26.
43.
National trends and disparities in the use of minimally invasive adult pyeloplasty.
Sukumar S, Sun M, Karakiewicz PI, Friedman AA, Chun FK, Sammon J, Ghani KR, Ravi P, Bianchi M, Jeong W, Shariat SF, Hansen J, Peabody JO, Elder JS, Menon M, Trinh QD.
J Urol. 2012 Sep;188(3):913-8. doi: 10.1016/j.juro.2012.05.013. Epub 2012 Jul 20.
44.
Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy.
Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, Shariat SF.
BJU Int. 2012 Jul 19. doi: 10.1111/j.1464-410X.2012.11356.x. [Epub ahead of print]
45.
Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy.
Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuchi E, Kassouf W, Martinez-Salamanca JI, Lotan Y, Seitz C, Pycha A, Zigeuner R, Karakiewicz PI, Scherr DS, Vickers AJ, Shariat SF.
Ann Surg Oncol. 2012 Dec;19(13):4337-44. doi: 10.1245/s10434-012-2499-8. Epub 2012 Jul 18.
46.
Protocol-based active surveillance for low-risk prostate cancer: anxiety levels in both men and their partners.
Seiler D, Randazzo M, Leupold U, Zeh N, Isbarn H, Chun FK, Ahyai SA, Baumgartner M, Huber A, Recker F, Kwiatkowski M.
Urology. 2012 Sep;80(3):564-9. doi: 10.1016/j.urology.2012.04.053. Epub 2012 Jul 7.
47.
Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerve-Sparing Radical Prostatectomy.
Gandaglia G, Suardi N, Gallina A, Abdollah F, Capitanio U, Salonia A, Colombo R, Bianchi M, Chun FK, Hansen J, Rigatti P, Montorsi F, Briganti A.
J Sex Med. 2012 Jun 27. doi: 10.1111/j.1743-6109.2012.02812.x. [Epub ahead of print]
48.
Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy.
Shariat SF, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joual A, Scherr DS, Gonen M.
Eur Urol. 2012 Jun 16.
49.
Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma.
Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF.
J Urol. 2012 Aug;188(2):398-404. doi: 10.1016/j.juro.2012.04.009. Epub 2012 Jun 13.
50.
Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy.
Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, Meskawi M, Schmitges J, Shariat SF, Chun FK, Perrotte P, Graefen M, Karakiewicz PI.
Urology. 2012 Aug;80(2):347-53. doi: 10.1016/j.urology.2012.04.043. Epub 2012 Jun 13.
51.
Predicting the risk of lymph node invasion during radical prostatectomy using the European Association of Urology guideline nomogram: a validation study.
Schmitges J, Karakiewicz PI, Sun M, Abdollah F, Budäus L, Isbarn H, Bianchi M, Trinh QD, Schlomm T, Chun FK, Graefen M, Steuber T.
Eur J Surg Oncol. 2012 Jul;38(7):624-9. doi: 10.1016/j.ejso.2012.04.005. Epub 2012 Apr 22.
PMID: 22531769 [PubMed - indexed for MEDLINE]
52.
Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection.
Walz J, Bladou F, Rousseau B, Laroche J, Salem N, Gravis G, Briganti A, Chun FK, Karakiewicz PI, Fournier G.
Urology. 2012 Mar;79(3):546-51. doi: 10.1016/j.urology.2011.11.036.
53.
Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification.
Shariat SF, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E, Kassouf W, Raman JD, Remzi M, Koppie TM, Bensalah K, Guo CC, Mikami S, Sircar K, Ng CK, Haitel A, Kabbani W, Chun FK, Wood CG, Scherr DS, Karakiewicz PI, Langner C.
Eur Urol. 2012 Aug;62(2):224-31. doi: 10.1016/j.eururo.2012.01.019. Epub 2012 Jan 24.
54.
Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma.
Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, Lotan Y, Shariat SF.
Eur Urol. 2012 Apr;61(4):854-5. doi: 10.1016/j.eururo.2011.12.055. Epub 2012 Jan 5. No abstract available.
55.
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment.
Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M.
Eur Urol. 2012 Feb;61(2):237-42. doi: 10.1016/j.eururo.2011.10.011. Epub 2011 Oct 21.
56.
Does low-risk prostate cancer detection change with repeat biopsies?
Najari BB, Rink M, Graefen M, Shariat SF, Chun FK.
Eur Urol. 2012 Jan;61(1):230-1. doi: 10.1016/j.eururo.2011.10.003. Epub 2011 Oct 18.
57.
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.
Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003.
58.
Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy.
Chromecki TF, Ehdaie B, Novara G, Pummer K, Zigeuner R, Seitz C, Pycha A, Lee RK, Cha EK, Karakiewicz PI, Ng C, Raman JD, Chun FK, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Bastian PJ, Martínez-Salamanca JI, Scherr DS, Shariat SF.
World J Urol. 2011 Aug;29(4):473-80. doi: 10.1007/s00345-011-0677-0. Epub 2011 Apr 17.
59.
Annual prostatectomy volume is related to rectal laceration rate after radical prostatectomy.
Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Hansen J, Eichelberg C, Perrotte P, Shariat SF, Menon M, Montorsi F, Graefen M, Karakiewicz PI.
Urology. 2012 Apr;79(4):796-803. doi: 10.1016/j.urology.2011.11.061.
60.
Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma.
Hellwinkel OJ, Asong LE, Rogmann JP, Sültmann H, Wagner C, Schlomm T, Eichelberg C.
Prostate Cancer Prostatic Dis. 2011 Mar;14(1):38-45. doi: 10.1038/pcan.2010.48. Epub 2010 Nov 23.
61.
Characterization of cells prepared by dendritic cell-tumor cell fusion.
Gottfried E, Krieg R, Eichelberg C, Andreesen R, Mackensen A, Krause SW.
Cancer Immun. 2002 Nov 7;2:15.
62.
[Multidetector Computed Tomography of Urolithiasis: Technique and Results.]
Karul M, Heuer R, Regier M.
Rofo. 2012 Nov 5.
63.
Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.
Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y.
J Urol. 2012 Feb;187(2):457-62. doi: 10.1016/j.juro.2011.10.031. Epub 2011 Dec 15.
64.
Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
Seiler D, Randazzo M, Klotz L, Grobholz R, Baumgartner M, Isbarn H, Recker F, Kwiatkowski M.
BJU Int. 2012 Jul;110(2):195-200. doi: 10.1111/j.1464-410X.2011.10707.x. Epub 2011 Nov 17.
65.
Decision curve analysis to compare 3 versions of Partin Tables to predict final pathologic stage.
Augustin H, Sun M, Isbarn H, Pummer K, Karakiewicz P.
Urol Oncol. 2012 Jul-Aug;30(4):396-401. doi: 10.1016/j.urolonc.2010.07.003. Epub 2010 Sep 29.
66.
Assessment of rates of lymph nodes and lymph node metastases in periprostatic fat pads in a consecutive cohort treated with retropubic radical prostatectomy.
Hansen J, Budäus L, Spethmann J, Schlomm T, Salomon G, Rink M, Haese A, Steuber T, Heinzer H, Huland H, Graefen M, Michl U.
Urology. 2012 Oct;80(4):877-82. doi: 10.1016/j.urology.2012.06.052. Epub 2012 Aug 28.
67.
Accuracy of HistoScanningT for the prediction of a negative surgical margin in patients undergoing radical prostatectomy.
Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L, Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M, Steuber T.
BJU Int. 2012 Aug 9. doi: 10.1111/j.1464-410X.2012
68.
Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.
Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.
Mod Pathol. 2012 Nov 30. doi: 10.1038/modpathol.2012.206
69.
Nodal involvement at nephrectomy is associated with worse survival: A stage-for-stage and grade-for-grade analysis.
Sun M, Bianchi M, Hansen J, Abdollah F, Trinh QD, Lughezzani G, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.
Int J Urol. 2012 Oct 8. doi: 10.1111/j.1442-2042.2012.03170.x. [Epub ahead of print]
70.
Proof of efficacy is not enough: contemporary management of patients with metastatic renal cell carcinoma with targeted therapy.
Sun M, Bianchi M, Hansen J, Trinh QD, Karakiewicz PI.
J Clin Oncol. 2012 Nov 1;30(31):3901; author reply 3902. doi: 10.1200/JCO.2012.43.7376. Epub 2012 Sep 17. No abstract available.
71.
In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy.
Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI, Sun M.
Eur Urol. 2012 Sep 7. doi:pii: S0302-2838(12)01022-6. 10.1016/j.eururo.2012.08.069.
72.
Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer?
Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, Briganti A, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.
J Sex Med. 2012 Nov;9(11):2961-9. doi: 10.1111/j.1743-6109.2012.02806.x. Epub 2012 Jun 6.
73.
Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged #75 years with multiple comorbidities.
Sun M, Bianchi M, Trinh QD, Hansen J, Abdollah F, Hanna N, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.
BJU Int. 2012 May 22. doi: 10.1111/j.1464-410X.2012.11254.x. [Epub ahead of print]
74.
A review of integrated staging systems for renal cell carcinoma.
Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Aug;62(2):303-14. doi: 10.1016/j.eururo.2012.04.049. Epub 2012 May 3. Review.
75.
Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis.
Sun M, Bianchi M, Hansen J, Trinh QD, Abdollah F, Tian Z, Sammon J, Shariat SF, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Oct;62(4):696-703. doi: 10.1016/j.eururo.2012.03.051. Epub 2012 Mar 31.
76.
Insights of modern pathology reports originating from prostate biopsy and radical prostatectomy specimens.
Sun M, Bianchi M, Hansen J, Karakiewicz PI.
Eur Urol. 2012 Jul;62(1):40-1. doi: 10.1016/j.eururo.2012.03.042. Epub 2012 Mar 30. No abstract available.
77.
Blood transfusions in radical prostatectomy: a contemporary population-based analysis.
Schmitges J, Sun M, Abdollah F, Trinh QD, Jeldres C, Budäus L, Bianchi M, Hansen J, Schlomm T, Perrotte P, Graefen M, Karakiewicz PI.
Urology. 2012 Feb;79(2):332-8. doi: 10.1016/j.urology.2011.08.079.
78.
Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series.
Hanna N, Sun M, Trinh QD, Hansen J, Bianchi M, Montorsi F, Shariat SF, Graefen M, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Apr;61(4):715-21. doi: 10.1016/j.eururo.2011.12.026. Epub 2011 Dec 22.
79.
Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample.
Trinh QD, Sammon J, Sun M, Ravi P, Ghani KR, Bianchi M, Jeong W, Shariat SF, Hansen J, Schmitges J, Jeldres C, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.
Eur Urol. 2012 Apr;61(4):679-85. doi: 10.1016/j.eururo.2011.12.027. Epub 2011 Dec 22.
80.
Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy.
Sun M, Abdollah F, Bianchi M, Trinh QD, Shariat SF, Jeldres C, Tian Z, Hansen J, Briganti A, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.
Eur J Cancer. 2012 Jul;48(10):1503-11. doi: 10.1016/j.ejca.2011.11.024. Epub 2011 Dec 21.
81.
A non-cancer-related survival benefit is associated with partial nephrectomy.
Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, Shariat SF, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Apr;61(4):725-31. doi: 10.1016/j.eururo.2011.11.047. Epub 2011 Dec 3.
82.
Oncologic Outcomes and Survival in pT0 Tumors After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results from of a Large Multicenter International Collaborative Study.
Rouprêt M, Xylinas E, Colin P, Kluth L, Karakiewicz P, Shariat SF.
Eur Urol. 2012 Sep 23. doi:pii: S0302-2838(12)01099-8. 10.1016/j.eururo.2012.09.031. [Epub ahead of print] No abstract available.
83.
Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma.
Xylinas E, Kluth L, Mangal S, Roupret M, Karakiewicz PI, Shariat SF.
World J Urol. 2012 Sep 18. [Epub ahead of print]
84.
Collaborative research networks as a platform for virtual multidisciplinary, international approach to managing difficult clinical cases: an example from the upper tract urothelial carcinoma collaboration.
Xylinas E, Rouprêt M, Kluth L, Scherr DS, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration.
Eur Urol. 2012 Nov;62(5):943-5. doi: 10.1016/j.eururo.2012.08.022. Epub 2012 Aug 20.
85.
Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy.
Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman JD, Lotan Y, Guillonneau B, Weizer A, Pycha A, Scherr DS, Seitz C, Sun M, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Gönen M, Shariat SF; UTUC Collaboration.
J Urol. 2012 Dec 14. doi:pii: S0022-5347(12)04848-3. 10.1016/j.juro.2012.09.036.
86.
Sex disparities in cancer mortality: The risks of being a man in the U.S.
Najari BB, Rink M, Li PS, Karakiewicz PI, Scherr DS, Shabsigh R, Meryn S, Schlegel PN, Shariat SF.
J Urol. 2012 Nov 30. doi:pii: S0022-5347(12)05774-6. 10.1016/j.juro.2012.11.153. [Epub ahead of print]
87.
Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.
Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A.
BJU Int. 2012 Nov 26. doi: 10.1111/j.1464-410X.2012.11455.x. [Epub ahead of print]
88.
Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling.
Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF.
Br J Cancer. 2012 Nov 20;107(11):1826-32. doi: 10.1038/bjc.2012.464.
89.
Predictive tools for prostate cancer staging, treatment response and outcomes.
Green DA, Osterberg EC, Xylinas E, Rink M, Karakiewicz PI, Scherr DS, Shariat SF.
Arch Esp Urol. 2012 Nov;65(9):787-807. English, Spanish.
90.
Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy.
Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, Scherr DS, Zerbib M, Shariat SF.
Ann Surg Oncol. 2012 Oct 26. [Epub ahead of print]
91.
Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins.
Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, Shariat SF.
J Urol. 2012 Sep 27. doi:pii: S0022-5347(12)05012-4. 10.1016/j.juro.2012.05.079. [Epub ahead of print]
92.
Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma.
Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, Shariat SF.
World J Urol. 2012 Sep 26.
93.
Cost-effective treatment of low-risk carcinoma not invading bladder muscle.
Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, Shariat SF, Lee RK.
BJU Int. 2012 Sep 7. doi: 10.1111/j.1464-410X.2012.11454.x. [Epub ahead of print]
94.
Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis.
Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joual A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr DS, Shariat SF.
Eur Urol. 2012 Jul 20. [Epub ahead of print]
95.
Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy.
Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Daneshmand S, Kassouf W, Durand M, Novara G, Fritsche HM, Burger M, Izawa JI, Brisuda A, Babjuk M, Pummer K, Shariat SF.
BJU Int. 2012 Jun 21. doi: 10.1111/j.1464-410X.2012.11322.x
96.
Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD, Lotan Y, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Seitz C, Walton T, Trinh QD, Karakiewicz PI, Matin S, Montorsi F, Zerbib M, Shariat SF; for the Upper Tract Urothelial Carcinoma Collaboration.
Eur Urol. 2012 May 4. [Epub ahead of print]
97.
A review of integrated staging systems for renal cell carcinoma.
Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Aug;62(2):303-14. doi: 10.1016/j.eururo.2012.04.049. Epub 2012 May 3. Review.
PMID: 22575911 [PubMed - indexed for MEDLINE]
98.
Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy.
Xylinas E, Rink M, Margulis V, Karakiewicz PI, Bensalah K, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration.
Eur Urol. 2012 Jul;62(1):e25-6. doi: 10.1016/j.eururo.2012.04.023. Epub 2012 Apr 17. No abstract available.
PMID: 22537797 [PubMed - indexed for MEDLINE]
99.
Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques.
Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, Shariat SF.
BJU Int. 2012 Nov;110(10):1463-70. doi: 10.1111/j.1464-410X.2012.11129.x. Epub 2012 Apr 13.
PMID: 22500557 [PubMed - in process]
100.
[Management of urinary incontinence after orthotopic urinary diversion].
Soave A, Dahlem R, Rink M, Ahyai S, Fisch M.
Urologe A. 2012 Apr;51(4):494-9. doi: 10.1007/s00120-012-2814-9. German.
PMID: 22476800 [PubMed - indexed for MEDLINE]
101.
Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence.
Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration (UTUCC).
Eur Urol. 2012 May;61(5):1069-70. doi: 10.1016/j.eururo.2012.02.042. Epub 2012 Feb 25
102.
Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.
Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; Bladder Cancer Research Consortium (BCRC); Upper Tract Urothelial Carcinoma Collaboration (UTUCC).
Eur Urol. 2012 Oct;62(4):677-84. Epub 2012 Feb 15.
103.
International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis.
Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, Fritsche HM, Matsumoto K, Walton TJ, Carballido J, Filippo Da Pozzo L, Bertini R, Ficarra V, Otto W, Karakiewicz PI, Pycha A, Fajkovic H, Naspro R, Scherr DS, Montorsi F, Shariat SF.
BJU Int. 2012 Sep;110(5):674-81. doi: 10.1111/j.1464-410X.2012.10930.x. Epub 2012 Feb 20.
104.
Can we apply nomograms derived in the United States to European patients? Yes, we can!
Rink M, Shariat SF.
Eur Urol. 2012 Jan;61(1):65-6. doi: 10.1016/j.eururo.2011.08.044. Epub 2011 Aug 27.
105.
[Additional classification "medicinal tumor therapy": statement by the German Society of Residents in Urology (GeSRU)].
Neuhäuser M, Schöne S, Meilinger M, Ruf C, Martinschek A.
Urologe A. 2012 May;51(5):721-3. doi: 10.1007/s00120-012-2857-y.
106.
Predicting metastasized seminoma using gene expression.
Ruf CG, Linbecker M, Port M, Riecke A, Schmelz HU, Wagner W, Meineke V, Abend M.
BJU Int. 2012 Jul;110(2 Pt 2):E14-20. doi: 10.1111/j.1464-410X.2011.10778.x. Epub 2012 Jan 13.
107.
A gene signature of primary tumor identifies metastasized seminoma.
Port M, Wang Y, Schmelz HU, Pottek T, Meineke V, Ruf C, Abend M.
Urol Oncol. 2011 Nov-Dec;29(6):764-73. doi: 10.1016/j.urolonc.2009.08.008. Epub 2009 Nov 27.
108.
[Value of targeted treatment for testicular cancer: from molecular approaches to clinical possibilities].
Martinschek A, Ruf CG, Sparwasser C, Schmelz HU.
Urologe A. 2008 Oct;47(10):1328-33. doi: 10.1007/s00120-008-1750-1. Review. German.
109.
Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
Schriefer P, Steurer S, Huland H, Graefen M.
J Clin Oncol. 2012 Nov 10;30(32):e341-4. doi: 10.1200/JCO.2012.43.1767. Epub 2012 Oct 1. No abstract available.
110.
High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer.
Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M.
Eur J Cancer. 2012 Dec 21. doi:pii: S0959-8049(12)00931-8. 10.1016/j.ejca.2012.11.035
111.
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer.
Flammiger A, Bayer F, Cirugeda-Kühnert A, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M.
APMIS. 2012 Nov;120(11):901-8. doi: 10.1111/j.1600-0463.2012.02924.x. Epub 2012 Jul 4.
112.
Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
Budäus L, Isbarn H, Tennstedt P, Salomon G, Schlomm T, Steuber T, Haese A, Chun F, Fisch M, Michl U, Heinzer H, Huland H, Graefen M.
BJU Int. 2012 Dec;110(11):1714-20. doi: 10.1111/j.1464-410X.2012.11147.x. Epub 2012 Apr 23.
113.
Controversies in the management of localized prostate cancer: radical prostatectomy still the standard of care.
Budäus L, Huland H, Graefen M; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME).
Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e24-9. doi: 10.1016/j.critrevonc.2010.09.004. Epub 2011 May 25.
114.
Influence of low-molecular-weight heparin dosage on red blood cell transfusion, lymphocele rate and drainage duration after open radical prostatectomy.
Schmitges J, Trinh QD, Jonas L, Budäus L, Larbig R, Schlomm T, Karakiewicz PI, Heinzer H, Huland H, Graefen M, Steuber T.
Eur J Surg Oncol. 2012 Nov;38(11):1082-8. doi: 10.1016/j.ejso.2012.08.002. Epub 2012 Aug 17.
115.
Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene.
Fleischmann A, Huland H, Mirlacher M, Wilczak W, Simon R, Erbersdobler A, Sauter G, Schlomm T.
Prostate. 2012 Jun 15;72(9):991-7. doi: 10.1002/pros.21504. Epub 2011 Oct 24.
116.
Advances in the management of high-risk localised and metastatic prostate cancer.
Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W.
BJU Int. 2012 Mar;109 Suppl 2:8-13. doi: 10.1111/j.1464-410X.2011.10871.x.
117.
Human prostate cancer in a clinically relevant xenograft mouse model: identification of #(1,6)-branched oligosaccharides as a marker of tumor progression.
Lange T, Ullrich S, Müller I, Nentwich MF, Stübke K, Feldhaus S, Knies C, Hellwinkel OJ, Vessella RL, Abramjuk C, Anders M, Schröder-Schwarz J, Schlomm T, Huland H, Sauter G, Schumacher U.
Clin Cancer Res. 2012 Mar 1;18(5):1364-73. doi: 10.1158/1078-0432.CCR-11-2900. Epub 2012 Jan 18.
118.
The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers.
Tennstedt P, Köster P, Brüchmann A, Mirlacher M, Haese A, Steuber T, Sauter G, Huland H, Graefen M, Schlomm T, Minner S, Simon R.
Int J Oncol. 2012 Jan;40(1):261-8. doi: 10.3892/ijo.2011.1216. Epub 2011 Sep 28.
119.
Effect of Nodal Metastases on Cancer-specific Mortality After Cytoreductive Nephrectomy.
Trinh QD, Sukumar S, Schmitges J, Bianchi M, Sun M, Shariat SF, Sammon JD, Jeldres C, Zorn KC, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Ann Surg Oncol. 2012 Dec 23. [Epub ahead of print]
120.
Active Surveillance for Low-risk Prostate Cancer: Some Questions Are Answered, but Many Questions Remain.
Graefen M, Schlomm T.
Eur Urol. 2012 Dec 13. doi:pii: S0302-2838(12)01471-6. 10.1016/j.eururo.2012.12.003.
121.
Controversies in the management of localized prostate cancer: radical prostatectomy still the standard of care.
Budäus L, Huland H, Graefen M; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME).
Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e24-9. doi: 10.1016/j.critrevonc.2010.09.004. Epub 2011 May 25.
122.
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.
Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Röhr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sültmann H, Lehrach H, Schweiger MR.
Cancer Discov. 2012 Nov;2(11):1024-35. doi: 10.1158/2159-8290.CD-12-0041. Epub 2012 Aug 28.
123.
Posterior musculofascial reconstruction after radical prostatectomy: a systematic review of the literature.
Rocco B, Cozzi G, Spinelli MG, Coelho RF, Patel VR, Tewari A, Wiklund P, Graefen M, Mottrie A, Gaboardi F, Gill IS, Montorsi F, Artibani W, Rocco F.
Eur Urol. 2012 Nov;62(5):779-90. doi: 10.1016/j.eururo.2012.05.041. Epub 2012 May 30.
124.
Venous thromboembolism after radical prostatectomy: the effect of surgical caseload.
Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Salomon G, Schlomm T, Perrotte P, Shariat SF, Montorsi F, Menon M, Graefen M, Karakiewicz PI.
BJU Int. 2012 Sep;110(6):828-33. doi: 10.1111/j.1464-410X.2012.10941.x. Epub 2012 Feb 7.
125.
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy.
Novara G, Ficarra V, Rosen RC, Artibani W, Costello A, Eastham JA, Graefen M, Guazzoni G, Shariat SF, Stolzenburg JU, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Wilson TG.
Eur Urol. 2012 Sep;62(3):431-52. doi: 10.1016/j.eururo.2012.05.044. Epub 2012 Jun 2. Review.
126.
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy.
Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll PR, Graefen M, Guazzoni G, Menon M, Patel VR, Shariat SF, Tewari AK, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Rosen RC, Wilson TG.
Eur Urol. 2012 Sep;62(3):382-404. doi: 10.1016/j.eururo.2012.05.047. Epub 2012 Jun 2. Review.
127.
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy.
Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, Guazzoni G, Menon M, Mottrie A, Patel VR, Van der Poel H, Rosen RC, Tewari AK, Wilson TG, Zattoni F, Montorsi F.
Eur Urol. 2012 Sep;62(3):418-30. doi: 10.1016/j.eururo.2012.05.046. Epub 2012 Jun 1. Review.
128.
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T.
Am J Pathol. 2012 Aug;181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026. Epub 2012 Jun 13.
129.
Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study.
Bianchi M, Trinh QD, Sun M, Meskawi M, Schmitges J, Shariat SF, Briganti A, Tian Z, Jeldres C, Sukumar S, Peabody JO, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI.
Can Urol Assoc J. 2012 Aug;6(4):245-50. doi: 10.5489/cuaj.12032.
130.
Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients.
Schlomm T, Tennstedt P, Huxhold C, Steuber T, Salomon G, Michl U, Heinzer H, Hansen J, Budäus L, Steurer S, Wittmer C, Minner S, Haese A, Sauter G, Graefen M, Huland H.
Eur Urol. 2012 Aug;62(2):333-40. doi: 10.1016/j.eururo.2012.04.057. Epub 2012 May 10.
131.
Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function.
Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, Stief C.
Eur Urol. 2012 Aug;62(2):273-86. doi: 10.1016/j.eururo.2012.04.047. Epub 2012 May 3. Review.
132.
Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery.
Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, Stief C.
Eur Urol. 2012 Aug;62(2):261-72. doi: 10.1016/j.eururo.2012.04.046. Epub 2012 May 3. Review.
133.
Does partial nephrectomy at an academic institution result in better outcomes?
Trinh QD, Schmitges J, Sun M, Sammon J, Shariat SF, Sukumar S, Zorn K, Bianchi M, Jeldres C, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
World J Urol. 2012 Aug;30(4):505-10. doi: 10.1007/s00345-011-0759-z. Epub 2011 Sep 9.
134.
Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort.
Trinh QD, Schmitges J, Bianchi M, Sun M, Shariat SF, Sammon J, Jeldres C, Zorn K, Sukumar S, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
BJU Int. 2012 Jul;110(2 Pt 2):E21-7. doi: 10.1111/j.1464-410X.2011.10701.x. Epub 2011 Nov 1.
135.
Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA.
Sun M, Abdollah F, Schmitges J, Bianchi M, Tian Z, Shariat SF, Zorn K, Pharand D, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.
BJU Int. 2012 Jun;109(12):1807-12. doi: 10.1111/j.1464-410X.2011.10569.x. Epub 2011 Sep 27.
136.
Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age.
Stahl PR, Kilgué A, Tennstedt P, Minner S, Krohn A, Simon R, Krause GV, Izbicki J, Graefen M, Sauter G, Schlomm T, Wilczak W.
Prostate. 2012 Jun 1;72(8):898-903. doi: 10.1002/pros.21492. Epub 2011 Sep 28.
137.
[Psychosocial predictors of utilization of medical rehabilitation services among prostate cancer patients].
Lehmann C, Beierlein V, Hagen-Aukamp C, Kerschgens C, Rhee M, Frühauf S, Otto J, Graefen M, Krüll A, Berger D, Koch U, Bergelt C.
Rehabilitation (Stuttg). 2012 Jun;51(3):160-70. doi: 10.1055/s-0031-1285893. Epub 2011 Dec 15. German.
138.
Open radical prostatectomy in the elderly: a case for concern?
Trinh QD, Schmitges J, Sun M, Shariat SF, Sukumar S, Tian Z, Bianchi M, Sammon J, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI.
BJU Int. 2012 May;109(9):1335-40. doi: 10.1111/j.1464-410X.2011.10554.x. Epub 2011 Sep 6.
139.
Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, Shariat SF.
Eur Urol. 2012 May;61(5):961-71. doi: 10.1016/j.eururo.2012.01.022. Epub 2012 Jan 23. Review.
140.
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.
Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI.
Ann Oncol. 2012 Apr;23(4):973-80. doi: 10.1093/annonc/mdr362. Epub 2011 Sep 2.
141.
Morbidity and mortality of radical prostatectomy differs by insurance status.
Trinh QD, Schmitges J, Sun M, Sammon J, Shariat SF, Zorn K, Sukumar S, Bianchi M, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Cancer. 2012 Apr 1;118(7):1803-10. doi: 10.1002/cncr.26475. Epub 2011 Aug 25
142.
Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States.
Trinh QD, Schmitges J, Sun M, Sukumar S, Sammon J, Shariat SF, Jeldres C, Bianchi M, Tian Z, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI.
Cancer. 2012 Apr 1;118(7):1894-900. doi: 10.1002/cncr.26527. Epub 2011 Sep 6.
143.
Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series.
Hanna N, Sun M, Trinh QD, Hansen J, Bianchi M, Montorsi F, Shariat SF, Graefen M, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Apr;61(4):715-21. doi: 10.1016/j.eururo.2011.12.026. Epub 2011 Dec 22.
144.
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.
Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC.
Eur Urol. 2012 Apr;61(4):664-75. doi: 10.1016/j.eururo.2011.11.053. Epub 2011 Dec 7. Review.
145.
Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M.
Eur Urol. 2012 Mar;61(3):584-92. doi: 10.1016/j.eururo.2011.11.043. Epub 2011 Dec 2.
146.
The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance.
van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, Remzi M, Marberger M.
BJU Int. 2012 Feb;109(3):360-6. doi: 10.1111/j.1464-410X.2011.10377.x. Epub 2011 Aug 26.
147.
Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations.
Mitropoulos D, Artibani W, Graefen M, Remzi M, Rouprêt M, Truss M; European Association of Urology Guidelines Panel.
Eur Urol. 2012 Feb;61(2):341-9. doi: 10.1016/j.eururo.2011.10.033. Epub 2011 Oct 29.
148.
Hospital volume is a determinant of postoperative complications, blood transfusion and length of stay after radical or partial nephrectomy.
Sun M, Bianchi M, Trinh QD, Abdollah F, Schmitges J, Jeldres C, Shariat SF, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.
J Urol. 2012 Feb;187(2):405-10. doi: 10.1016/j.juro.2011.10.025. Epub 2011 Dec 15.
149.
The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis.
Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schröder F, van Cangh P, van Poppel H, Spahn M.
Adv Urol. 2012;2012:612707. doi: 10.1155/2012/612707. Epub 2012 Jan 31.
150.
The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers.
Tennstedt P, Köster P, Brüchmann A, Mirlacher M, Haese A, Steuber T, Sauter G, Huland H, Graefen M, Schlomm T, Minner S, Simon R.
Int J Oncol. 2012 Jan;40(1):261-8. doi: 10.3892/ijo.2011.1216. Epub 2011 Sep 28.
151.
A comment on the International Society of Geriatric Oncology guidelines: evidence-based advice for the clinical setting.
Fitzpatrick JM, Graefen M, Payne HA, Scotté F, Aapro MS.
Oncologist. 2012;17 Suppl 1:31-5.
152.
Is radical prostatectomy a useful therapeutic option for high-risk prostate cancer in older men?
Graefen M, Schlomm T.
Oncologist. 2012;17 Suppl 1:4-8.
153.
[DGFIT: Immune and targeted therapy in urologic oncology - what can be expected?].
Hegele A, Heinzer H, Rüttinger D, Siebels M.
Aktuelle Urol. 2012 Jul;43(4):219-26. German.
154.
High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers.
Minner S, Luebke AM, Kluth M, Bokemeyer C, Jänicke F, Izbicki J, Schlomm T, Sauter G, Wilczak W.
Histopathology. 2012 Sep;61(3):445-53. doi: 10.1111/j.1365-2559.2012.04240.x. Epub 2012 Mar 28.
155.
[Focal prostate cancer therapy : Capabilities, limitations and prospects.]
Baumunk D, Blana A, Ganzer R, Henkel T, Köllermann J, Roosen A, Machtens S, Salomon G, Sentker L, Witzsch U, Köhrmann KU, Schostak M; Arbeitsgruppe für Fokale und Mikrotherapie.
Urologe A. 2012 Oct 18. [Epub ahead of print] German.
156.
TRANSRECTAL SONOELASTOGRAPHY IN THE DETECTION OF PROSTATE CANCERS: A META-ANALYSIS.
Salomon G.
BJU Int. 2012 Jul 12. doi: 10.1111/j.1464-410X.2012.11349.x. [Epub ahead of print]
157.
Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel.
Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, Frauscher F, Kovacs G, Matin SF, Mischi M, Pinto P, Rastinehad A, Rouviere O, Salomon G, Polascik T, Walz J, Wijkstra H, Marberger M.
BJU Int. 2012 Oct;110(7):942-8. doi: 10.1111/j.1464-410X.2012.11072.x. Epub 2012 Mar 30.
158.
Haemodynamics and cardiac function during robotic-assisted laparoscopic prostatectomy in steep Trendelenburg position.
Haas S, Haese A, Goetz AE, Kubitz JC.
Int J Med Robot. 2011 Dec;7(4):408-13. doi: 10.1002/rcs.410. Epub 2011 Aug 3.
159.
Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion.
Tombal B, Ameye F, de la Taille A, de Reijke T, Gontero P, Haese A, Kil P, Perrin P, Remzi M, Schröder J, Speakman M, Volpe A, Meesen B, Stoevelaar H.
World J Urol. 2012 Apr;30(2):251-6. doi: 10.1007/s00345-011-0721-0. Epub 2011 Jul 1.
